TRANSLATE BIO Stock Price, News & Analysis

Telesis Bio Inc. (TBIO) is a public company based in San Diego, California that focuses on automated DNA and mRNA synthesis technologies for research and therapeutic discovery. The company describes itself as empowering scientists to create synthetic biology-enabled solutions for many of humanity’s challenges by enabling rapid, accurate and reproducible writing of DNA and mRNA directly in their own laboratories.

Telesis Bio is known as the inventor of the industry-standard Gibson Assembly® method and for developing what it describes as the first commercial automated benchtop DNA and mRNA synthesis system. Its award-winning BioXp® systems consolidate, automate and optimize the synthesis, cloning and amplification workflow, allowing DNA and RNA to be produced at scale in days or hours instead of weeks or months. According to company descriptions, scientists around the world use these systems to accelerate the design-build-test paradigm in areas such as precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy.

Core technologies and platforms

A central focus for Telesis Bio is its proprietary Gibson SOLA™ Enzymatic Synthesis platform. The company states that Gibson SOLA is a non-toxic, high-fidelity and scalable DNA synthesis technology that enables fully enzymatic, on-site synthesis of long and complex nucleic acids. The platform is described as a reagent platform with a suite of software tools that can be deployed on standard automated liquid-handling equipment, supporting overnight, on-demand synthesis of DNA and mRNA in customers’ own labs.

According to Telesis Bio, the Gibson SOLA platform allows customers to take full control of their nucleic acid supply chain, protect intellectual property and retain ownership of data and insights that can be used in AI-powered drug discovery models. The company highlights that Gibson SOLA can be integrated onto many third-party automation platforms as well as its own BioXp systems, and is designed to synthesize high-fidelity synthetic oligonucleotides, genes and transfection-ready mRNA at a wide range of scales in as little as overnight.

The BioXp® automation platform is positioned by the company as a benchtop system for rapid synthesis of DNA and mRNA. Telesis Bio states that the BioXp system and its associated mRNA synthesis kits enable rapid benchtop synthesis of high-quality, transfection-ready mRNA in timeframes that can allow researchers to continue discovery work within days instead of weeks. The system is described as consolidating and automating the entire synthesis, cloning and amplification workflow, and as being used for applications such as biologics drug discovery, vaccine and therapeutic development, genome editing and cell and gene therapy.

Business focus and applications

Telesis Bio describes itself as a leading provider of DNA and mRNA synthesis solutions that enable researchers to accelerate therapeutic discovery through advanced, flexible and rapid automated synthesis technology in their own labs. Company materials emphasize enabling on-premises or on-site biofoundry capabilities, with Gibson SOLA and BioXp platforms intended to support high-throughput, on-demand synthesis of high-fidelity DNA and mRNA.

The company highlights that DNA and mRNA are critical raw materials for therapeutic research and molecular diagnostics, and that demand for high-quality and increasingly complex nucleic acids is large and growing. Telesis Bio states that its technologies allow researchers to move away from complicated and unreliable external supply chains by producing nucleic acids internally using standard liquid-handling automation, while keeping proprietary data within their own organizations.

Use cases described by Telesis Bio include precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. The company also notes that its technologies are used to accelerate design-build-test cycles and to support development of mRNA-based vaccines and other biopharma products under strategic collaborations.

Strategic collaborations and partnerships

Telesis Bio has publicly discussed strategic collaborations and agreements related to its core platforms. The company reports a strategic research collaboration and license agreement with Pfizer based on its proprietary SOLA platform, which utilizes enzymatic DNA synthesis technology for potential application in mRNA-based vaccines and other biopharma products. Telesis Bio has also announced a co-development and marketing agreement with an automation provider and a collaboration with Beckman Coulter Life Sciences to integrate Gibson SOLA Enzymatic Synthesis technology with Beckman Coulter Life Sciences automation for on-premises biofoundry capabilities.

In addition, Telesis Bio has disclosed a license agreement with Regeneron Pharmaceuticals, Inc. to deploy the Gibson SOLA platform at Regeneron’s R&D core facilities. According to the company, this deployment is intended to support automated, high-throughput, on-demand gene synthesis in Regeneron’s labs, enabling overnight, on-site synthesis of high-fidelity DNA and mRNA and reducing design-to-build timelines from weeks to hours.

Capital markets and trading status

Telesis Bio has been described in company communications as a public company. The company previously traded on The Nasdaq Global Select Market under the symbol TBIO. In a public announcement, Telesis Bio stated that it notified Nasdaq of its decision to voluntarily delist its common stock and to deregister the stock under Section 12(b) of the Securities Exchange Act of 1934. The company indicated that it intended to file a Form 25 with the U.S. Securities and Exchange Commission to remove its common stock from listing on Nasdaq and that, following delisting, trading in its common stock could occur in privately negotiated sales and potentially on an over-the-counter market operated by OTC Markets Group Inc.

Subsequent company descriptions refer to Telesis Bio as a public company based in San Diego and identify the symbol TBIO on OTC markets. Investors researching TBIO should review the company’s most recent public disclosures to understand its current trading venue and reporting obligations.

Strategic focus and restructuring

Telesis Bio has publicly discussed a strategic focus on expanding adoption of its Gibson SOLA enzymatic DNA synthesis platform and BioXp mRNA solutions. The company has indicated that it is concentrating efforts on Gibson SOLA for DNA and mRNA high-throughput drug discovery applications and on using the BioXp automation platform for mRNA synthesis workflows. Company communications also describe restructuring activities and cost reductions intended to align its cost structure with this commercial focus.

In addition, Telesis Bio has mentioned divesting an Eton subsidiary, restructuring operations to reduce costs, and expanding distribution channels for BioXp benchtop synthesis solutions through non-exclusive distribution agreements. These steps are presented by the company as part of its effort to support commercial adoption of Gibson SOLA and BioXp-based workflows.

Position within synthetic biology and laboratory automation

Across its public materials, Telesis Bio emphasizes its role in synthetic biology and laboratory automation by enabling on-demand, on-premises synthesis of DNA and mRNA. The company’s platforms are described as supporting high-fidelity, scalable and non-toxic synthesis, and as allowing researchers to maintain control over both nucleic acid production and associated data. By combining enzymatic synthesis chemistry, automation-compatible reagent platforms and software tools, Telesis Bio positions its technology as a way to streamline complex workflows that might otherwise depend on external service providers.

For investors and researchers, TBIO represents exposure to a company focused on automated nucleic acid synthesis, synthetic biology workflows and collaborations with biopharmaceutical and automation partners. Anyone evaluating Telesis Bio should review its latest public filings and announcements for updated information on its strategy, collaborations and capital structure.